Abstract | PURPOSE: PATIENTS AND METHODS: Subjects included 6 women aged < or = 65 years with breast cancer and bone-only metastases at M. D. Anderson Cancer Center. The activity of (166)Ho-DOTMP was calculated to deliver a therapeutic absorbed dose of 22 Gy (n = 3) or 28 Gy (n = 3) to the marrow. Treatment was followed by autologous stem cell transplantation to circumvent the anticipated myelosuppresion. Median follow-up time was 40 months. RESULTS: All subjects showed prompt hematologic recovery. No patient experienced grade 3/4 acute toxicity aside from myelosuppression. Two patients developed hemorrhagic cystitis 2 years after therapy. One patient developed myelodysplastic syndrome but was found to have had pre-existing trisomy 8. Two patients remained progression free without evidence of disease for more than 6 years. Five women experienced disease relapse (4 at extraosseous sites) and died of progressive disease. Median time to progression was 10.4 months. CONCLUSION:
|
Authors | Naoto T Ueno, Jonas A de Souza, Daniel Booser, Kazutaka Nakayama, John Madewell, Richard E Wendt 3rd, Gabriel N Hortobagyi, Donald Podoloff, Richard E Champlin |
Journal | Clinical breast cancer
(Clin Breast Cancer)
Vol. 9
Issue 3
Pg. 173-7
(Aug 2009)
ISSN: 1938-0666 [Electronic] United States |
PMID | 19661041
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Organophosphorus Compounds
- 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid)
|
Topics |
- Adult
- Bone Neoplasms
(secondary, therapy)
- Bone and Bones
(drug effects, radiation effects)
- Breast Neoplasms
(pathology)
- Combined Modality Therapy
- Female
- Humans
- Middle Aged
- Organophosphorus Compounds
(adverse effects, pharmacokinetics)
- Peripheral Blood Stem Cell Transplantation
- Pilot Projects
- Treatment Outcome
|